Cargando…
Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
Ever since relevant bioengineering technologies have sufficiently matured to the platformizable commercialization stage, a slew of money has flocked to the cell and gene therapy market over the last few years, resulting in an abundance of clinical studies in the field. Newer modalities have brought...
Autores principales: | Lee, SungKyung, Lee, Jong Hyuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998493/ https://www.ncbi.nlm.nih.gov/pubmed/36908458 http://dx.doi.org/10.3389/fpubh.2023.1109873 |
Ejemplares similares
-
Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021) -
Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction
por: Kim, Sungju, et al.
Publicado: (2020) -
Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023) -
Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
por: Vogler, Sabine, et al.
Publicado: (2011) -
Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
por: Atikeler, Enver Kagan, et al.
Publicado: (2016)